Good long-term outcomes for drug-eluting stents

April 4, 2012
Good long-Term outcomes for drug-Eluting stents
Meta-analysis of randomized clinical trials suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, or recurrent myocardial infarction, but data from observational studies indicate an increased risk of ST with DES use, according to research published in the April 1 issue of The American Journal of Cardiology.

(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, or recurrent myocardial infarction, but data from observational studies indicate an increased risk of ST with DES use, according to research published in the April 1 issue of The American Journal of Cardiology.

To investigate the long-term outcomes of DESs and bare metal stents (BMSs) after primary (PPCI), Eric L. Wallace, D.O., of the University of Kentucky in Lexington, and associates conducted a meta-analysis of eight RCTs involving 5,797 patients and five with 4,650 patients.

In the RCTs, the researchers found that patients receiving sirolimus- or paclitaxel-eluting stents, compared with BMSs, had a significantly lower risk of target lesion revascularization (odds ratio [OR], 0.48), target vessel revascularization (OR, 0.53), and major adverse cardiac events (OR, 0.69). ST, mortality, and recurrent were not significantly different between the groups. In the observational studies, at three or more years follow-up, there was a small but significant increase in ST with DES use (OR, 1.62), with no evidence of recurrent myocardial infarction. DES use was associated with significantly reduced mortality compared with BMS use (OR, 0.65).

"This meta-analysis of RCTs examining the long-term outcomes of first-generation DESs versus BMSs in PPCI, DES use resulted in decreased repeat revascularization with no increase in ST, mortality, or recurrent myocardial infarction," the authors write. "The meta-analysis of observational studies demonstrates a small increase in the risk of ST and improved survival associated with DES use."

Explore further: Results of the DEB-AMI Trial reported at TCT 2011

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011

A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Recommended for you

Scientists identify protein linked to chronic heart failure

May 26, 2017

Researchers in Japan have identified a receptor protein on the surface of heart cells that promotes chronic heart failure. The study, "Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction," which ...

Hypertension in young adults shows long-term heart risks

May 19, 2017

Otherwise healthy young people with high systolic blood pressure over 140 are at greater risk for future artery stiffening linked to an increased risk of stroke as well as possible damage to the kidneys and brain, new research ...

Team discovers way to help heart failure patients

May 17, 2017

Shortness of breath is the No.1 complaint of people suffering from heart failure. Now a University of Guelph researcher has discovered its surprising cause - and an effective treatment - in a groundbreaking new study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.